Clinical trial NCT04107298: Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon
Official title: A Prospective, Multi-Center, Single-Arm, Feasibility Study to Assess the Safety and Performance WIth the SUNDANCE™ DruG Coated Balloon for the Treatment of De Novo or Restenotic Lesions in Infra-Popliteal Arteries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease
Critical Lower Limb Ischemia
Lead sponsor: SurModics, Inc.
Sponsor class: INDUSTRY
First posted: 2019-09-27
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and performance of the Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.

Detailed description: SWING is a prospective, multi-center, single-arm, feasibility study to assess the safety and performance of the Sundance™ drug coated balloon for the treatment of de novo or restenotic lesions in infra-popliteal Arteries. Approximately 35 subjects will be treated at up to 8 sites.

Eligibility criteria: Clinical Inclusion Criteria

* Subject is ≥18 years.
* Subject has target limb Rutherford classification 4 or 5. Rutherford classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (i.e., no more than 7 Rutherford class 3 subjects may be enrolled in the study).
* Subject has provided written informed consent and is willing to comply with study follow-up requirements.

Clinical Exclusion Criteria

* Subject has acute limb ischemia.
* Subject underwent intervention involving the target vessel (not a proximal inflow vessel) within the previous 90 days.
* Subject previously underwent PTA of the target lesion vessel using a DCB or DES.
* Subject has had prior vascular intervention in the contralateral limb within 14 days before the planned study index procedure or subject has planned vascular intervention in the contralateral limb within 30 days after the index procedure.
* Subjects with heel gangrene, deep heel ulcers, osteomyelitis of tarsal or metatarsal bones (which extends beyond the metatarsal head immediately adjacent to the metatarso-phalangeal joint), and subjects with exposed vital structures (e.g., medial or lateral malleolus).
* Subjects requiring pedal angioplasty.
* Subjects that are non-ambulatory and confined to bed.
* Women who are pregnant, breast-feeding or intend to become pregnant or men who intend to father children during the time of the study.
* Subject has history of Class 3 (and above) congestive heart failure (CHF) in past 6 months.
* Subject has life expectancy less than 12 months.
* Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
* Subject has known hypersensitivity to sirolimus
* Subject has a known contraindication to the intended concomitant medications.
* Subject is allergic to ALL antiplatelet treatments.
* Subject has impaired renal function (i.e. serum creatinine level ≥2.5 mg/dL or ≥221 µmol/L).
* Subject had major limb amputation on the affected side in last year or has planned major limb amputation.
* Subject is receiving immunosuppressant therapy.
* Subject has known or suspected active infection at the time of the index procedure.
* Subject has platelet count \<100,000/mm3 or \>700,000/mm3.
* Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure.
* Subject is diagnosed with coagulopathy or other disorders which are contraindications for treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
* Subject has history of stroke within the past 3 months.
* Subject has a history of myocardial infarction within the past 30 days.
* Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
* Subject is incarcerated, mentally incompetent, or abusing drugs or alcohol.
* Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
* Subject has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure.
* Subject had previous bypass surgery of the target lesion.
* Subject had previously implanted stent in target lesion.
* Subject had previous treatment of the target vessel with thrombolysis or surgery.
* Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.

Angiographic Inclusion Criteria

* The target lesion/vessel must meet all of the following angiographic criteria for the subject to participate in the trial:
* De novo lesion(s) or non-stented restenotic lesion
* Target lesion location starts at the P3 segment and terminates at 1cm above the ankle. Note: Isolated P3 lesion is not allowed. If a lesion starts in the P3 segment, it must continue into the infrapopliteal.
* Target vessel diameter ≥2 mm and ≤4 mm, based on visual estimation.
* Target lesion must have angiographic evidence of ≥70% stenosis by operator visual estimate.
* Chronic total occlusions may be included only after successful, uncomplicated wire crossing of target lesion. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion. Use of re-entry/crossing devices is not allowed. Crossing may be performed retrograde, but treatment must be performed antegrade.

Uncomplicated: Upon visual inspection, no occurrence of embolization, perforation, or occurrence of flow-limiting dissection.

* Target lesion(s) must be ≤230 mm in total lesion(s) length by operator visual estimate. A maximum of two lesions may be treated. The two lesions may be in one infrapopliteal vessel or in two distinct infrapopliteal vessels. Note: Tandem lesions may be considered a single lesion if they are separated by ≤30 mm.
* After pre-dilatation, the target lesion has ≤70% residual stenosis, absence of a flow limiting dissection (Grade D or greater) and treatable with available device matrix.
* A patent inflow artery free from significant stenosis (≥50% stenosis) as confirmed by angiography.
* At least one patent native outflow artery to the ankle or foot distal to the lesion being treated, free from significant stenosis (≥50% stenosis) as confirmed by angiography.

Angiographic Exclusion Criteria

* Aneurysm in the target vessel or proximal inflow artery.
* Inflow lesion or occlusion in the ipsilateral Iliac, SFA, popliteal arteries with length ≥15 cm.
* Significant stenosis (≥ 50%) in inflow lesion or occlusion in the ipsilateral iliac, SFA, popliteal arteries left untreated.
* Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, or re-entry devices.
* Significant target vessel tortuosity or other parameters prohibiting access to the target lesion.
* Presence of thrombus in the target vessel.

Primary outcomes:
measure: Primary Safety Endpoint: Number of Participants with a composite of freedom from Major Adverse Limb Event (MALE) and perioperative death
timeFrame: 30 Days
measure: Primary Efficacy Endpoint: Rate of Late Lumen Loss (LLL)
timeFrame: 6 Months
Secondary outcomes:
measure: Rate of Device Success
timeFrame: Acute/Periprocedural
measure: Rate of Technical Success
timeFrame: Acute/Periprocedural
measure: Rate of Procedure Success
timeFrame: Acute/Periprocedural
measure: Rate of Restenosis
timeFrame: 6 Months or prior
measure: Number of Participants with Primary Patency
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: Major Adverse Event (MAE) rate
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: Amputation Free Survival
timeFrame: 6 Months, 12 Months, 24 Months
measure: Hemodynamic outcomes
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: Change in Rutherford-Becker Classification
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: EQ-5D
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: Walking Impairment Questionnaire (WIQ)
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
measure: Vascular Quality of Life Questionnaire (VascuQol)
timeFrame: 30 Days, 6 Months, 12 Months, 24 Months
Other outcomes:
Locations:
city: Perth
country: Australia
facility: Royal Perth Hospital
city: Randwick
country: Australia
facility: Prince of Wales Private Hospital
city: St Leonards
country: Australia
facility: Royal North Shore Hospital
city: Graz
country: Austria
facility: Universitäts Klinikum Graz
city: Bad Krozingen
country: Germany
facility: Universitäts-Herzzentrum Freiburg Bad Krozingen
city: Sonneberg
country: Germany
facility: MEDINOS Kliniken des Landkreises Sonneberg GmbH
city: Riga
country: Latvia
facility: Paul Stradins University Hospital
city: Auckland
country: New Zealand
facility: Auckland City Hospital
Study officials:
References: